Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Serum levels of interleukin 1-β, tumor necrosis factor-α, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies

  • 33 Accesses

  • 42 Citations


Seronegative spondylarthropathies are disorders with the same predisposing antigen, namely HLA B27, a class I molecule of the HLA system. The mechanisms of the different diseases are unknown, and there is no proof of immune system participation. We have investigated patients with spondylarthropathies in order to search for an immunological component in the pathophysiology of these disorders, by measuring the serum level of two inflammatory cytokines-IL1β and TNFα-by a radioimmunological assay and the serum level of two soluble T cell activation markers-soluble IL2 receptor and soluble CD8-by an enzyme-linked immunosorbent assay. The choice of soluble CD8 can be explained by the strong link between HLA B27 and spondylarthropathies. Our series compared 24 patients to 24 healthy matched controls. A similar IL1β serum level was observed in both groups, while in the patients there was a nonsignificant increase in the TNFα level, a significant decrease in the soluble IL2 receptor level and a significant increase in the soluble CD8 serum level. The normal or moderately increased serum IL1β and TNFα levels in the disease group do not exclued a local role for these cytokines in the synovium or other inflammatory areas. However, we found a higher soluble CD8 serum level in the patient group. Most of these patients were in clinical excerbation of their disease. As the serum level of soluble CD8 is well correlated with T CD8 lymphocyte activation, our data suggest that this lymphocyte subset is stimulated and consequently probably involved in seronegative spondylarthropathies.

This is a preview of subscription content, log in to check access.


  1. 1.

    McGuisan LE, Geczy AF, Edmonds JP (1985) The immunopathology of ankylosing spondylitis. A review. Semin Arthritis Rheum 15: 81–105

  2. 2.

    Balkwill FR, Burke F (1989) The cytokine network. Immunol Today 10: 299–304

  3. 3.

    Dinarello CA, Mier JW (1987) Current concepts: lymphokines. N Engl J Med 317: 940–945

  4. 4.

    Platanias LC, Vogelzang NJ (1990) Interleukin 1: biology, pathophysiology and clinical prospects. Am J Med 89: 621–629

  5. 5.

    Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316: 379–385

  6. 6.

    Old JD (1985) Tumor necrosis factor: TNF Science 230: 630–632

  7. 7.

    Smith KA (1988) Interleukin 2: inception, impact nd implications. Science 240: 1169–1176

  8. 8.

    Smith KA (1987) The two-chain structure of high-affinity IL2 receptors. Immunol Today 8: 11–13

  9. 9.

    Rubin LA, Kurman CC, Fritz ME, Biddison E, Boutin B, Yarchoan B, Nelson DL (1985) Soluble IL2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172–3177

  10. 10.

    Tonkinson BE, Brown MC, Stephen HIP, Carrabis S, Sullivan JL (1989) Soluble CD8s during T cell activation. J Immunol 142: 2230–2236

  11. 11.

    Amor B, Dougados M, Mijiyawa M (1990) Critères de classification des spondylarthropathies. Rev Rhum 57: 85–89

  12. 12.

    Kidd BL, Moore K, Walters MT, Smith JL, Cawley MID (1989) Immunohistological features of synovitis in ankylosing spondylitis: a comparison with rheumatoid arthritis. Ann Rheum Dis 48: 92–98

  13. 13.

    Houssiau FA, Nagant de Deuxchaisnes C (1990) Cytokines and inflammatory arthritides. Clin Exp Rheum 8: 531–533

  14. 14.

    Campen DH, Horwitz DA, Quismorio FP Jr, Ehresmann GR, Martin WJ (1988) Serum levels of interleukin 2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 31: 1358–1364

  15. 15.

    Maury CPJ, Teppo AM (1989) Cachectin Tumor Necrosis factor alpha in the circulation of patients with rheumatic disease. Int J Tiss Reac 11: 189–193

  16. 16.

    Raziuddin Syed, Al-Janadi MA, Al-Wabel AA (1991) Soluble interleukin 2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus. J Rheumatol 18: 831–836

  17. 17.

    Carpenter AB, Eisenbeis CH, Carrabis S, Brown MC, Ip SH (1990) Soluble interleukin 2 receptor: elevated level in serum and synovial fluid of patients with rheumatoid arthritis. J Clin Lab Anal 4: 130–134

  18. 18.

    Rubin LA, Snow KM, Kurman CC, Nelson DL, Keystone EC (1990) Serial levels of soluble IL2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol 17: 597–602

  19. 19.

    Rubin LA (1990) The soluble IL2 receptor in rheumatic disease. Arthritis Rheum 33: 1145–1148

  20. 20.

    Rubin LA, Nelson DL, (1990) The soluble IL2 receptor: biology, function and clinical application, Ann Intern Med 113: 619–627

  21. 21.

    Fujimoto J, Levy S, Levy R (1983) Spontaneous release of the Leu-2 (T8) molecule from human T cells. J Exp Med 159: 752–766

  22. 22.

    Symons JA, Woods NC, Giovine NS, Duff GW (1990) Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol 80: 354–359

  23. 23.

    Maimone D, Reder AT (1991) Soluble CD8 levels in the XSF and serum of patients with multiple sclerosis. Neurology 41: 851–854

  24. 24.

    Symons JA, Wood NC, Giovine FS, Duff GW (1988) Soluble IL2 receptor in rheumatoid arthritis. Correlation with disease activity, IL1 and IL2 inhibition. J Immunol 141: 2612–2618

  25. 25.

    Wood NC, Symons JA, Duff GW (1988) Serum IL2 receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun 1: 353–361

  26. 26.

    Zielinsky CL, Pesau B, Müller C (1990) Soluble interleukin 2 receptor and soluble CD8 antigen in active rheumatoid arthritis. Clin Immunol Immunopathol 57: 74–82

  27. 27.

    Arend WP, Dayer JM (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33: 305–315

  28. 28.

    Panayi GS (1990) Cytokines and anticytokines. Clin Exp Rheumatol 8: 65–66

  29. 29.

    Firestein GS, Alvaro-Garcia JM, Maki R (1990) Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144: 3347–3353

  30. 30.

    Wendling D, Racadot E, Viel JF (1991) Soluble IL2 receptor in patients with ankylosing spondylitis. Arthritis Rheum 34: 1622–1623

Download references

Author information

Correspondence to P. C. Acquaviva.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Toussirot, E., Lafforgue, P., Boucraut, J. et al. Serum levels of interleukin 1-β, tumor necrosis factor-α, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 13, 175–180 (1994). https://doi.org/10.1007/BF00390264

Download citation

Key words

  • Seronegative spondylarthropathies
  • Cytokines
  • Lymphocyte activation
  • CD8